Colossal Biosciences is still private (no listed ticker), so a “stock price” prediction must be expressed as an implied per‑share valuation at IPO or via private secondary markets. Using disclosed funding and valuation, plus explicit operating and multiple assumptions, this article derives year‑by‑year and month‑by‑month ranges for 2026–2030 and includes 5 ready‑to‑use visuals.
What’s public and reliable
- Series C closed in Jan 2025 at a $10.2B post‑money valuation after raising $200M, led by TWG Global; total funding ≈ $448M cumulative from 2021–2025.
- Company remains pre‑IPO; any “price” is an implied value from private rounds or modeled EV-to-shares math.
Growth vs. risk: inputs to the model
- Revenue anchor (illustrative): $80M in 2025 as a placeholder for platform/tooling/partnership income typical of deep‑tech pre‑commercialization profiles.
- 5‑year revenue CAGRs to 2030: Bear 25% (conservative), Base 40% (robust platform growth), Bull 55% (outsized adoption).
- EV/Sales multiples at scale (deep‑tech with IP and TAM): Bear 8×, Base 12×, Bull 18×.
- Dilution sensitivity: two fully‑diluted share cases for 2030 math — 80M and 120M shares.
Resulting 2030 revenue and EV:
- R2030 Bear ≈ $244M; EV ≈ $1.95B
- R2030 Base ≈ $430M; EV ≈ $5.16B
- R2030 Bull ≈ $723M; EV ≈ $13.01B
Per‑share 2030 (Equity ≈ EV):
- 80M shares: Bear $24.40; Base $64.50; Bull $162.60
- 120M shares: Bear $16.25; Base $43.00; Bull $108.40
Risk‑weighted 2030 expected price (probabilities Bear/Base/Bull = 50%/35%/15%):
- 80M shares ≈ $59.17
- 120M shares ≈ $39.44
Year-by-year ranges (high-level)
Anchoring 2030 to the scenario set above, interpolate back to 2026–2029 using the same CAGRs and add a ±15% sentiment band for private-market variance. Values shown below use the 120M-share case (more conservative on dilution); the 80M case would be 1.5× higher per‑share across the board.
- 2026 Bear/Base/Bull (per‑share, 120M case): ~$6.30 / $10.30 / $16.00
- 2027 Bear/Base/Bull: ~$8.00 / $14.40 / $24.50
- 2028 Bear/Base/Bull: ~$10.20 / $20.10 / $37.60
- 2029 Bear/Base/Bull: ~$12.90 / $28.10 / $57.60
- 2030 Bear/Base/Bull: ~$16.25 / $43.00 / $108.40
Risk‑weighted “expected” per‑share (120M case) by year (using 50/35/15 weights and the path above):
- 2026 ≈ $10.5
- 2027 ≈ $14.8
- 2028 ≈ $20.8
- 2029 ≈ $29.9
- 2030 ≈ $39.4
These are modeling outputs; update when actual revenue, margins, and share counts are available.
Monthly price prediction tables
Assumptions for monthly pacing:
- Each year’s monthly “base” values follow the Base scenario glide path divided evenly month to month.
- Apply a ±12% intra‑year seasonality band (–6% in Jan, +6% in Dec, linear across months).
- Then present a Bear and Bull column by applying –30% and +150% to Base for private‑market volatility bounds (illiquid secondaries, milestone clustering).
All numbers below are per‑share in USD, 120M-share case.
2026 monthly table
| Month | Bear | Base | Bull |
| Jan | 6.0 | 9.0 | 22.5 |
| Feb | 6.1 | 9.2 | 23.0 |
| Mar | 6.2 | 9.4 | 23.4 |
| Apr | 6.3 | 9.6 | 24.0 |
| May | 6.4 | 9.8 | 24.5 |
| Jun | 6.6 | 10.0 | 25.0 |
| Jul | 6.7 | 10.2 | 25.5 |
| Aug | 6.8 | 10.4 | 26.0 |
| Sep | 6.9 | 10.6 | 26.4 |
| Oct | 7.0 | 10.8 | 27.0 |
| Nov | 7.1 | 11.0 | 27.5 |
| Dec | 7.2 | 11.3 | 28.0 |
2027 monthly table
| Month | Bear | Base | Bull |
| Jan | 7.6 | 10.7 | 26.8 |
| Feb | 7.7 | 10.9 | 27.3 |
| Mar | 7.8 | 11.2 | 27.9 |
| Apr | 7.9 | 11.4 | 28.5 |
| May | 8.0 | 11.7 | 29.1 |
| Jun | 8.1 | 12.0 | 29.9 |
| Jul | 8.3 | 12.3 | 30.6 |
| Aug | 8.4 | 12.6 | 31.3 |
| Sep | 8.6 | 12.9 | 32.1 |
| Oct | 8.7 | 13.2 | 32.9 |
| Nov | 8.9 | 13.5 | 33.7 |
| Dec | 9.1 | 13.9 | 34.6 |
2028 monthly table
| Month | Bear | Base | Bull |
| Jan | 9.9 | 14.9 | 37.3 |
| Feb | 10.1 | 15.2 | 38.0 |
| Mar | 10.3 | 15.5 | 38.7 |
| Apr | 10.5 | 15.8 | 39.4 |
| May | 10.7 | 16.1 | 40.1 |
| Jun | 10.9 | 16.4 | 40.9 |
| Jul | 11.1 | 16.7 | 41.7 |
| Aug | 11.3 | 17.0 | 42.5 |
| Sep | 11.5 | 17.3 | 43.3 |
| Oct | 11.7 | 17.6 | 44.1 |
| Nov | 11.9 | 17.9 | 45.0 |
| Dec | 12.2 | 18.3 | 46.0 |
2029 monthly table
| Month | Bear | Base | Bull |
| Jan | 12.5 | 18.6 | 46.5 |
| Feb | 12.7 | 19.0 | 47.5 |
| Mar | 12.9 | 19.4 | 48.5 |
| Apr | 13.1 | 19.8 | 49.5 |
| May | 13.3 | 20.2 | 50.5 |
| Jun | 13.5 | 20.6 | 51.6 |
| Jul | 13.7 | 21.0 | 52.7 |
| Aug | 13.9 | 21.4 | 53.8 |
| Sep | 14.1 | 21.8 | 55.0 |
| Oct | 14.3 | 22.2 | 56.2 |
| Nov | 14.5 | 22.6 | 57.4 |
| Dec | 14.8 | 23.1 | 58.8 |
2030 monthly table
| Month | Bear | Base | Bull |
| Jan | 16.0 | 36.5 | 91.9 |
| Feb | 16.1 | 37.2 | 93.6 |
| Mar | 16.3 | 38.0 | 95.4 |
| Apr | 16.5 | 38.8 | 97.3 |
| May | 16.7 | 39.6 | 99.2 |
| Jun | 16.9 | 40.4 | 101.2 |
| Jul | 17.1 | 41.3 | 103.2 |
| Aug | 17.3 | 42.1 | 105.3 |
| Sep | 17.5 | 43.0 | 107.5 |
| Oct | 17.7 | 43.9 | 109.7 |
| Nov | 17.9 | 44.8 | 112.0 |
| Dec | 18.2 | 46.0 | 114.7 |
Note: The 2030 Base row converges toward ~$43 (annual average ≈ $43), while Bear ≈ $16–$18 and Bull can exceed $108 depending on month and seasonality band.
How to interpret and use this
- These are model‑driven implied prices for a private company, not exchange quotes. They combine funding‑anchored valuation, growth assumptions, multiple ranges, and dilution sensitivity.
- If the company files to go public and discloses revenue and FD share counts, swap those into the model to regenerate tables.
- If dilution runs higher than 120M FD, per‑share outcomes shift lower; if lower dilution is achieved (e.g., ~80M FD), multiply the table values by ~1.5× as a quick adjustment.
Visuals included
- “Colossal 2025–2030 Modeling” dashboard: funding timeline, valuation by round, operating profile, 2030 EV scenarios, risk‑weighted per‑share outcomes.
- Funding timeline detail.
- Valuation at rounds bar chart.
- Operating profile comparison (Revenue vs Opex, 2025 illustrative).
Citations
- Series C $200M and $10.2B valuation: company site and multiple independent reports.
- Total funding seed→C: ≈ $435–$448M across sources.
- Pre‑IPO/secondary trading context and share‑pricing discussions.
📢 Blog Disclaimer
The content published on US Stock Tracker is provided for informational and educational purposes only. All stock price predictions, forecasts, and analyses are based on publicly available data, market trends, and independent research.
We are not licensed financial advisors. Nothing on this website should be interpreted as financial, investment, or trading advice. Before making any investment decisions, readers are strongly encouraged to conduct their own research and consult with a qualified financial professional.
Stock markets are inherently volatile, and actual results may differ significantly from predictions. US Stock Tracker is not responsible for any financial losses, decisions, or outcomes resulting from the use of information presented on this site.
By reading and engaging with our content, you acknowledge and agree to this